JPRN-jRCT1041210163招募中2 期
Phase II study of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for the paitents with advanced hepatocellular carcinoma refractory or unsuitable for immune-checkpoint inhibitor
Yamashita Tatsuya0 个研究点目标入组 60 人开始时间: 2022年3月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •clinically diagnosed as hepatocellular carcinoma; unsuitable for local therapy; refractory or unsuitable for immune checkpoint inhibitor; Preserved liver function; 20 years or older; ECOG Performance status <=2; preservation of major organ function; written informed consent
排除标准
- •refractory ascites or pleural effusion; risky varices; double cancer; metastases to central nervous system; severe complication; pregnant or lactating women, or women of childbearing potential; mental disorder; patients who investigator regards as inappropriate for candidate
研究者
相似试验
招募中
2 期
AC Lenvatinib plus CisplatiHepatocellular carcinomaJPRN-jRCT1041220110Yamashita Tatsuya24
已完成
2 期
EOPARD trialHepatocellular carcinomaJPRN-jRCTs031180019Ikeda Masafumi36
已完成
2 期
Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCCRadiotherapyLenvatinibHepatocellular CarcinomaNCT04791176Cancer Institute and Hospital, Chinese Academy of Medical Sciences64
进行中（未招募）
2 期
A phase II study of lenvatinib (E7080/MK-7902) in combination with carboplatin pemetrexed and pembrolizumab (MK-3475) for patients with pretreated advanced non-squamous non-small cell lung cancer harboring EGFR mutationsAdvanced non-squamous non-small cell lung cancer harboring EGFR mutationsJPRN-jRCT2031220147Takahashi Kazuhisa30
已完成
1 期
A Study of Lenvatinib Plus Nivolumab in Participants With HepatocellularCarcinoma, HepatocellularJPRN-jRCT2080223794Eisai Co., Ltd.26